Uncategorized

Lilly, FDA retatrutide biologic dispute comes to a head as submission nears

Published

on

A legal dispute between the FDA and Eli Lilly over whether the highly anticipated obesity candidate retatrutide is indeed a biologic has come to a head as the company prepares to submit the medicine for approval.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version